Clinical trials: Myasthenia
AIRE Deficiency
Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies
Studying genetic predisposition in autoimmune neurological diseases could help improve diagnostic accuracy and offer new treatment possibilities
- Trial name
- NAD-AIRE (NCT06941584)
- Testing
- Test for AQP4, AChR, LGI1, and CASPR2 autoantibodies using cell-based assay, AIRE single gene sequencing, Molecular typing of HLA class I and II alleles
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
This is a multi-country, prospective safety study of pregnant women exposed to efgartigimod or efgartigimod PH20 SC any time within 25 days prior to conception or any time during pregnancy.
- Trial name
- NCT06299748
- Testing
- Efgartigimod
- Where
- 4 sites in United States, Germany and 2 more
- Volunteers
- 279 people
- Sponsor
- argenx
Myasthenia Gravis
Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) as a corticosteroid (CS)-sparing agent in…
- Trial name
- NCT02473965
- Testing
- IGIV-C
- Where
- 39 sites in United States, Belgium and 8 more
- Volunteers
- 60 people
- Sponsor
- Grifols Therapeutics LLC
Myasthenia Gravis, Myasthenia Gravis, Juvenile Form
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in the treatment of pediatric refractory gMG based on change from Baseline in the Quantitative Myasthenia Gravis…
- Conditions
- Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized
- Trial name
- NCT03759366
- Testing
- Eculizumab
- Where
- 11 sites in United States, Japan
- Volunteers
- 12 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN)
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
This is an investigator-initiated, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of MTM-H-001 in adult participants with B-cell-related…
- Conditions
- Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN), Multiple Sclerosis, Myasthenia Gravis (MG)
- Trial name
- ArchAid-002 (NCT07593911)
- Testing
- MTM-H-001 Injection
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Beijing GoBroad Hospital
Generalized Myasthenia Gravis
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG).
- Trial name
- NCT03315130
- Testing
- zilucoplan (RA101495)
- Where
- 30 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- Ra Pharmaceuticals
Experimental Myasthenia
Effect of Core Strength Training on Wushu C-level Difficulty Movements ,12 Weeks of Core Strength Training
This paper designs the core strength training scheme based on the query and reference of relevant literature and the characteristics of C-level difficult movements of Wushu.
- Trial name
- NCT05024071
- Testing
- Wushu athletes in the experimental group used a Swiss ball for 12 weeks of core strength training, Wushu athletes in the experimental group used a balance board for 12 weeks of core strength training
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universiti Putra Malaysia
Myasthenia Gravis
Pyridostigmine and Amifampridine for Myasthenia Gravis
A randomized, double-blind, placebo controlled, crossover intervention study evaluating the effect of pyridostigmine (part 1) and amifampridine (part 2) in Myasthenia Gravis (MG).
- Trial name
- IMPACT-MG (NCT05919407)
- Testing
- Pyridostigmine, Amifampridine (base) with modified release
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Leiden University Medical Center
Myasthenia Gravis
Exercise for Stable Myasthenia Gravis
Generalized fatigue in myasthenia gravis results in physical deconditioning that reduces fitness and increases risk of obesity, hypertension, elevated cholesterol and type 2 diabetes.
- Trial name
- NCT01047761
- Testing
- Exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Baltimore VA Medical Center
Myasthenia Gravis Crisis
Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis
Efgartigimod in Myasthenic Crisis Background Myasthenia gravis (MG) is a prevalent autoimmune disorder affecting neuromuscular junctions, characterized by weakness in skeletal muscles.
- Trial name
- NCT06688253
- Testing
- IV efgartigimod
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- Rambam Health Care Campus
Myasthenia Gravis
A Study of TAK-079 in People With Generalized Myasthenia Gravis
Myasthenia gravis is an autoimmune condition that causes muscle weakness. Autoimmune means the body makes antibodies that attack its own cells and tissues. These types of antibodies are also known as autoantibodies.
- Trial name
- NCT04159805
- Testing
- TAK-079
- Where
- 50 sites in United States, Canada and 4 more
- Volunteers
- 36 people
- Sponsor
- Takeda
Myasthaenia Gravis
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.
- Trial name
- NCT06765161
- Testing
- efgartigimod administration
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Clinique Neuro-Outaouais
Myasthenia Gravis
Application of Artificial Intelligence in Precision Medicine and Healthcare
This study aims to propose an intelligent health robot that utilizes remote intelligent robots to assist patients with disease-related issues, enabling them to address their problems promptly.
- Trial name
- NCT06879210
- Testing
- Mobile device.(phone)
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Yi Ting Yeh
Generalized Myasthenia Gravis
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to <18 years with generalized Myasthenia Gravis (gMG).
- Trial name
- roMyG (NCT06149559)
- Testing
- rozanolixizumab
- Where
- 9 sites in Italy, Japan and 2 more
- Volunteers
- 14 people
- Sponsor
- UCB Biopharma SRL
Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
This is an open label, single-site, dose-escalation study in up to 25 participants with refractory autoimmune diseases of nervous system.
- Conditions
- Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized, Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Trial name
- NCT06485232
- Testing
- Universal BCMA CAR-T, Universal CD19 CAR-T, Universal BCMA CAR-T; Universal CD19 CAR-T
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Xuanwu Hospital, Beijing
Myasthenia Gravis, Generalized
Study of Telitacicept in Generalized Myasthenia Gravis
The purpose of this study is to evaluate the efficacy and safety of Telitacicept in the treatment of patients with generalized myasthenia gravis.
- Trial name
- NCT05737160
- Testing
- Telitacicept
- Where
- 51 sites in China
- Volunteers
- 114 people
- Sponsor
- RemeGen Co., Ltd.
Lambert-Eaton Myasthenic Syndrome
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
OBJECTIVES: I. Evaluate the safety and effectiveness of 3,4-diaminopyridine (DAP) in the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS). II. Determine the side-effects and benefits associated with DAP.
- Trial name
- NCT00004832
- Testing
- 3,4-diaminopyridine
- Volunteers
- 26 people
- Sponsor
- FDA Office of Orphan Products Development
Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome
3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
The purpose of this study is to determine the effectiveness and adverse effects of 3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS).
- Trial name
- LEMS (NCT00872950)
- Testing
- 3,4-DIAMINOPYRIDINE
- Where
- United States
- Sponsor
- Lahey Clinic
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis.
- Conditions
- AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
- Trial name
- NCT07284420
- Testing
- Efgartigimod IV, Empasiprubart IV
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 70 people
- Sponsor
- argenx
Myasthenia Gravis
TCM Tongue Diagnosis and Syndrome Differentiation in Myasthenia Gravis Compared to Healthy Controls
Myasthenia gravis primarily results from neuromuscular junction dysfunction and damage, leading to chronic muscle weakness. While combined traditional and Western medicine treatments are now common, TCM tongue diagnosis remains a…
- Trial name
- NCT06754020
- Testing
- Heart Rate Variability,HRV - ANSWatch, Traditional Chinese Medicine Tongue Imaging
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Yi Ting Yeh